Targeted RNA Editing
Technology Platforms

RecoRNA (Guangzhou) Biotechnology Co., Ltd, is a pioneering company developing RNA-targeted editing technologies to address diseases that currently lack effective treatments. We focus on unmet clinical needs across genetic diseases, neurological disorders, chronic conditions, and other therapeutic areas, advancing precision medicine through cutting-edge RNA-based innovations.

RecoRNA has built a comprehensive RNA therapy platform that includes a world leading single-base RNA editing design engine powered by the industry’s largest ADAR natural substrate library, an RNA fragment excision tool, and the AI driven ATOMIC screening platform. These breakthrough technologies enable the discovery and development of novel therapeutics that overcome the limitations of traditional small-molecule and biologic drugs. Our platforms are designed to address major challenges across frameshift mutation diseases, point mutation genetic disorders, metabolic diseases and Immuno-oncology–addressable cancers, while avoiding the irreversible off target safety risks associated with DNA level gene editing therapies.

Xu Xin (Hong Kong) Biotechnology Co., Ltd., a wholly-owned subsidiary of RecoRNA (Guangzhou) Biotechnology Co., Ltd, is located in the Hong Kong Science & Technology Park. The company has built an AI-driven technology platform that overcomes key bottleneck in traditional drug R&D and accelerates the entire process from target identification to hit-molecule design, lead optimization, and candidate selection.